JDRF T1D Fund β 2020 Investments
4 investments dated 2020 Β· listed companies and verified rows first Β· show all
Biotechnology company developing safe and effective oral formulations of therapies traditionally limited to injections using ionic liquid technology
BiotechSaratoga, US
Mitragotri Mitragotri(Executive Officer, Director)Ravi Srinivasan(Executive Officer, Director)in
Co-investors7G BioVenturesSanofi Ventures
Portfolio company acquired by Novo Nordisk for $1.1B USD.
Co-investorsAmorChemGenesys CapitalNew Enterprise Associates (NEA)Tarnagulla VenturesadMare BioInnovationsAmgen Ventures+2 more
Repertoire's Decode platform focuses on mapping the immune synapse β the interactions between T cell receptors, epitopes, and HLA molecules β to support the development of medicines targeting cancer and other diseases.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtech
Torben Straight Nissen(Chief Executive Officer)inAnthony Coyle(President, Research and Development)inRobert Andtbacka(Chief Medical Officer)inJohn Delyani(Chief Business Officer)inJan Kisielow(Chief Scientific Officer, Repertoire Immune Medicines (Switzerland) Ltd.)in
Co-investorsFlagship PioneeringSoftBank Vision Fund
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.